Prota Therapeutics
Business Services · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
477 C/o Fb Rice Reception L 33, Melbourn...Website
www.protatherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Prota Therapeutics
Prota Therapeutics is a late clinical-stage biotech company focused on developing allergen oral immunotherapies to treat food allergies, with a particular emphasis on peanut allergies. The company leverages over two decades of research led by Professor Mimi Tang at the Murdoch Childrens Research Institute in Melbourne, Australia. Their lead product, PRT120, is phase-3 ready and aims to improve the quality of life for individuals suffering from food allergies. Prota's treatments are investigational and not yet approved for marketing.Explore more
Prota Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Prota Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Prota Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Prota Therapeutics launches new products
Check out if Prota Therapeutics is spiking on competitors!
Check if Prota Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Prota Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Prota Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Prota Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Prota Therapeutics
Recommended Actions
Reach out to Masked Content who joined Prota Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Prota Therapeutics
Compare insights from companies similar to Prota Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Prota Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Prota Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Prota Therapeutics.
Prota Therapeutics financials insights
Gather financial insights about Prota Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$21M
Prota Therapeutics Tech Stack
A closer look at the technologies used by Prota Therapeutics
See more technologies
Prota Therapeutics News & Media
Prota Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick Machado
MELBOURNE, Australia, July 24, 2024 (GLOBE NEWSWIRE) -- Prota Therapeutics, an Australian biotechnology company focused on the development of novel oral immunotherapy treatments against peanut allergy, today announced the appointment of Patrick Machado as a Chair to its Board of Directors, effective immediately.Prota Therapeutics' CEO Mimi Tang honoured at BioMelbourne Network's Women in Leadership Awards 2024
MELBOURNE, Australia, April 29, 2024 /PRNewswire/ -- Prota Therapeutics' CEO Professor Mimi Tang has been honoured in the prestigious 2024 BioMelbourne Network Women in Leadership Awards. Professor Tang's exceptional work as a lead researcher for the Murdoch Children's Research Institute (MCRI) and her groundbreaking contributions to the understanding and treatment of food allergies have earned her this year's Distinguished Leadership Award. As the CEO of Prota Therapeutics, Professor Tang has dProta Therapeutics US $21 Million Financing Led by SPRIM Global Investments
MELBOURNE, Jan 16, 2024 - (ACN Newswire) - Prota Therapeutics Pty Ltd (Prota), an Australian biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy, today announced financing of US$21 million in equity and debt financing. The round, led by Singapore-based SPRIM Global Investments (SGI), will help the company prepare for a Phase 3 clinical investigation of the company's PRT120 oral therapy for peanut allergy. "SPRIM brings valuable
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Prota Therapeutics
Sign Up For FreeTo access detailed company insights
Prota Therapeutics is a late clinical-stage biotech company focused on developing allergen oral immunotherapies to treat food allergies, with a particular emphasis on peanut allergies. The company leverages over two decades of research led by Professor Mimi Tang at the Murdoch Childrens Research Institute in Melbourne, Australia. Their lead product... Read More
